Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001493215-25-000037
Filing Date
2025-11-14
Accepted
2025-11-14 08:24:27
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8440
2 JOINT FILING AGREEMENT ex-99-11142025_011125.htm EX-99.1 2455
  Complete submission text file 0001493215-25-000037.txt   12733
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Subject) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90885 | Film No.: 251481424
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 40 10TH AVENUE 7TH FLOOR NEW YORK NY 10014
Business Address 40 10TH AVENUE 7TH FLOOR NEW YORK NY 10014 646-597-6980
RTW INVESTMENTS, LP (Filed by) CIK: 0001493215 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G